<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="589">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521754</url>
  </required_header>
  <id_info>
    <org_study_id>1.02.9001</org_study_id>
    <secondary_id>Addendum C.AD.1</secondary_id>
    <nct_id>NCT01521754</nct_id>
  </id_info>
  <brief_title>Product Surveillance Registry- Deep Brain Stimulation for Epilepsy</brief_title>
  <acronym>MORE</acronym>
  <official_title>Medtronic Registry for Epilepsy (MORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic International Trading Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic International Trading Sarl</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <authority>Finland: Ethics Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Portugal: Ethics Committee for Clinical Research</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational registry is to evaluate the long-term effectiveness,
      safety and performance of market-released Medtronic Neuromodulation products for Deep Brain
      Stimulation (DBS) for the treatment of refractory epilepsy. In addition, healthcare resource
      use and patient reported outcomes, such as health related quality of life will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction

      The purpose of this observational registry is to evaluate the long-term effectiveness,
      safety and performance of market-released Medtronic Neuromodulation products for Deep Brain
      Stimulation (DBS) for the treatment of refractory epilepsy. In addition, healthcare resource
      use and patient reported outcomes, such as health related quality of life will be assessed.

      Enrollment and Duration Patients meeting the eligibility criteria for the implantation of
      the Medtronic® DBS™ Therapy for Epilepsy will be included in the registry. Approximately 200
      patients meeting all the eligibility criteria will be prospectively enrolled over an
      expected two-year period.

      Approximately 30 centers, mainly from across Europe will participate. Center selection could
      also be extended to sites outside Europe.

      Each patient will perform follow-up visits according to clinical practice.

      The estimated duration of the registry will be approximately 49 months (24 months for the
      enrollment phase, 24 months for follow-up visits and 1 month for final data collection).

      Inclusion and exclusion criteria Inclusion criteria

        -  Fulfilling the criteria of labeling indications of Medtronic® DBS™ Therapy for
           Epilepsy.

        -  Patient with diagnosis of refractory epilepsy as defined by 1981 ILAE (International
           League Against Epilepsy) classification, who have been implanted or will be implanted
           with Medtronic® DBS™ Therapy for Epilepsy.

        -  For both cohorts, completed at least two full consecutive months diary information on
           seizure type and frequency prior to DBS implant (seizure type should be classified at
           least as simple partial, complex partial, partial evolving to secondarily generalized
           seizures, and generalized). In regard to the prospective cohort, the patient will be
           conditionally enrolled at the enrolment visit, and the criterion will be reassessed at
           the baseline visit.

        -  Patient or patient's legally authorized representative able to understand and to
           provide written informed consent and/or authorization for access to and use of health
           information, as required by an institution's IRB/MEC or local law and regulations.

      Exclusion criteria

        -  Incomplete and/or unreliable patient seizure diary based on the physician's judgment

        -  Patient is currently enrolled in or plans to enroll in any concurrent drug, surgery
           and/or device study that may confound the results of this registry.

      Registry Procedures

      After the physician has determined that a patient meets all of the eligibility criteria, the
      physician will enroll the patient in the registry by completing the Patient Informed Consent
      or Data Release Consent Form process.

      Once enrolled, patients will be followed at least for 24 months or until their
      discontinuation from the registry.

      Follow-up visits will occur according to clinical practice, approximately every 6 months
      after the first visit post-implant.

      Adverse events and/or device events will be reported as they occur.

      Data collection will occur at the following time points:

        -  Enrollment Visit

        -  Baseline Visit

        -  Implant Visit

        -  Follow-up Visits (over a period of minimum two years)

      The following follow-up visits are scheduled according to the clinical practice,
      approximately every 6 months for at least two years or till the closure of the registry.

      Primary Objective The primary efficacy objective is to evaluate the change in seizure rate
      from baseline over 2 years following DBS implant.

      Secondary Objectives

        -  To characterize the demographics of the population undergoing Medtronic® DBS™ Therapy
           for Epilepsy,

        -  To assess adverse events related to the device, implant procedure, and/or therapy.

        -  To characterize seizure type and severity.

        -  To characterize co-treatments.

        -  To assess the change in health-related quality of life following DBS by means of
           QOLIE-31 (Quality of life in epilepsy-31) and SF-36 (Short-form 36).

        -  To evaluate changes in depression score over time Exploratory objectives

        -  To assess use of health care resources specifically associated with epilepsy following
           DBS.

        -  To characterize DBS implant technique and device/feature utilization.

        -  To assess the factors that better predict the response level of the DBS therapy.

      Sample Size Justification The purpose of the registry is essentially observational and
      exploratory; hence no sample size calculation was performed.

      Safety objectives

        -  To assess adverse events

        -  To characterize the incidence of sudden unexpected death in epilepsy (SUDEP)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Seizure rate</measure>
    <time_frame>Participants will be followed for the duration of the registry, an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the change in seizure rate from baseline over 2 years following DBS implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure type and severity</measure>
    <time_frame>Participants will be followed for the duration of the registry, an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize seizure type and severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression score assessment</measure>
    <time_frame>Participants will be followed for the duration of the registry, an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate changes in depression score over time. BDI-II score is obtained by adding the score circled for each of the 21 items, the change of the BDI-II score is calculated as the difference between value at baseline phase and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL)</measure>
    <time_frame>Participants will be followed for the duration of the registry, an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the change in health-related quality of life following DBS by means of QOLIE-31 (Quality of life in epilepsy-31) and SF-36 (Short-form 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events characterization</measure>
    <time_frame>Participants will be followed for the duration of the registry, an expected average of 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess adverse events related to the device, implant procedure, and/or therapy.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Perspective</arm_group_label>
    <description>Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
    <description>Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults diagnosed with refractory epilepsy characterized by partial-onset seizures, with or
        without secondary generalization
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilling the criteria of labeling indications of Medtronic® DBS™ Therapy for
             Epilepsy.

          -  Patient with diagnosis of refractory epilepsy as defined by 1981 ILAE (International
             League Against Epilepsy) classification, who have been implanted or will be implanted
             with Medtronic® DBS™ Therapy for Epilepsy.

          -  For both cohorts, completed at least two full consecutive months diary information on
             seizure type and frequency prior to DBS implant (seizure type should be classified at
             least as simple partial, complex partial, partial evolving to secondarily generalized
             seizures, and generalized). In regard to the prospective cohort, the patient will be
             conditionally enrolled at the enrolment visit, and the criterion will be reassessed
             at the baseline visit.

          -  Patient or patient's legally authorized representative able to understand and to
             provide written informed consent and/or authorization for access to and use of health
             information, as required by an institution's IRB/MEC or local law and regulations.

        Exclusion Criteria:

          -  Incomplete and/or unreliable patient seizure diary based on the physician's judgment

          -  Patient is currently enrolled in or plans to enroll in any concurrent drug, surgery
             and/or device study that may confound the results of this registry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Boon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariane Beaumann</last_name>
    <phone>+41 (0)21 803 8467</phone>
    <email>ariane.beaumann@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregory Beth</last_name>
    <email>gregory.beth@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Pataraia, Dr.</last_name>
      <phone>0043-1 40400</phone>
      <phone_ext>3433/3139</phone_ext>
      <email>ekaterina.pataraia@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ekaterina Pataraia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University &amp; Hospital of Tampere - Neurology and Rehabilitation</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Peltola, Dr.</last_name>
      <phone>+358 33 11 64 713</phone>
      <email>jukka.peltola@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jukka Peltola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn -AöR-</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Elger, Prof.</last_name>
      <phone>0049 (0228) 287 11574</phone>
      <email>christian.elger@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Elger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schulze-Bonhage, Prof.</last_name>
      <phone>0049 (0)761-270</phone>
      <phone_ext>54250</phone_ext>
      <email>andreas.schulze-bonhage@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Schulze-Bonhage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologie und Epilepsiezentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Stodieck, MD</last_name>
      <phone>+49 -40- 5077 3507</phone>
      <email>s.stodieck@alsterdorf.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Stodieck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lang, Dr.</last_name>
      <phone>0049 431 597 8550</phone>
      <email>n.lang@neurologie.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Nicolas Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München -Großhadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soheyl Noachtar, Prof.</last_name>
      <phone>0049 89 7095</phone>
      <phone_ext>3691</phone_ext>
      <email>Soheyl.Noachtar@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Soheyl Noachtar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Rona, Dr.</last_name>
      <email>Sabine.Rona@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Sabine Rona, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Országos Idegtudományi Intézet / National Institute of Neurosciences</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loránd Erőss, MD</last_name>
      <email>eross@oiti.hu</email>
    </contact>
    <investigator>
      <last_name>Loránd Erőss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pécs Clinical Centre (PTE KK)</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>József Janszky, Prof.</last_name>
      <email>jozsef.janszky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>József Janszky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ. Ospedaliero-Universitario-Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Scerrati, Prof.</last_name>
      <phone>+39 071 596 4578</phone>
      <email>mscerrati@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Scerrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AO Santa Maria della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Eleopra, Dr.</last_name>
      <phone>0039 0432 554608</phone>
      <email>eleopra.roberto@aoud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Eleopra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEIN Heemstede</name>
      <address>
        <city>Heemstede</city>
        <zip>2103</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Zwemmer, Dr.</last_name>
      <phone>31(0)23-5588940</phone>
      <email>jzwemmer@sein.nl</email>
    </contact>
    <investigator>
      <last_name>Jack Zwemmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Expertisecentrum Voor Epileptologie-Kempenhaeghe</name>
      <address>
        <city>Heeze</city>
        <zip>65 5591 VE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Boon, Prof.</last_name>
      <phone>(040) 227 90 22</phone>
      <email>Paul.Boon@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Paul Boon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEIN</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Ardesch, Dr.</last_name>
      <phone>(038) 8457185</phone>
      <email>jardesch@sein.nl</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Ardesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Hageman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie - Neurology</name>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Bosak, Dr</last_name>
      <phone>0048-605-155 098</phone>
      <email>magdalenabosak@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Magdalena Bosak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Gawlowicz, Dr.</last_name>
      <phone>81 537-42-29</phone>
      <email>jgawlowicz@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jacek Gawlowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonçalves Ferreira, Prof.</last_name>
      <email>ajgonfer@fm.ul.pt</email>
    </contact>
    <investigator>
      <last_name>Antonio Gonçalves Ferreira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João E.P.E.</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Vaz, Prof.</last_name>
      <email>ruimcvaz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rui Vaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gordon, Dr.</last_name>
      <email>Lisa.gordon@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Lisa Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinisk Neurovetenskap</name>
      <address>
        <city>Umea</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patric Blomstedt, Prof.</last_name>
      <phone>+46907850000</phone>
      <email>patric.blomstedt@neuro.umu.se</email>
    </contact>
    <investigator>
      <last_name>Patric Blomstedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Kumlien, MD</last_name>
      <phone>+46 18-611 50 03</phone>
      <email>Eva.kumlien@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Eva Kumlien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dougall McCorry, Dr</last_name>
      <email>dougall.mccorry@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS16 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nik Patel, Dr</last_name>
      <phone>+441173403953</phone>
      <email>nik.patel@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Howard Faulkner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W 8BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Pavese, Dr.</last_name>
      <email>nicola.pavese@csc.mrc.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yvonne Hart, Dr</last_name>
      <email>yvonne.hart@nuth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Rowe, Dr</last_name>
      <email>jeremy.rowe@sch.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>April 9, 2015</lastchanged_date>
  <firstreceived_date>January 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
